The use of a methylene blue and glyceryl trinitrate-based cream for the treatment of chronic anal fissures: a phase II randomized pilot trial from a referral coloproctological unit

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

Chronic anal fissures (CAFs) are the second most common anorectal disease.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A phase II randomized single-centre triple-blinded study was carried out in a tertiary proctology unit on patients with CAF.

The enrollment started after local ethics committee approval (study n. 6461, protocol approval n. 0045085).

How the Study Was Run

The design is described as randomized and pilot.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Methylene blue (non-peptide stack partner) study would be practical.

Eligible consecutive patients were randomized to one of three different groups, each receiving a different ointment.

What Was Measured

PubMed files the paper under topics including Administration, Topical, Chronic Disease, Fissure in Ano, Methylene Blue, Nitroglycerin, Ointments and Pilot Projects.

The authors tagged it with the keywords Anal fissure, Anal pain, Blue cream, Glyceryl trinitrate and REALISE scoring system.

What This Means in Plain Language

The paper is a randomized and pilot study of Methylene blue (non-peptide stack partner).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Techniques in coloproctology), a journal based in Italy.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.